- Home
- ABLV vs DXR Comparison
ABLV vs DXR Comparison
Compare ABLV & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | DXR |
|---|---|---|
| Founded | 2015 | 1970 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 61.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABLV | DXR |
|---|---|---|
| Price | $0.76 | $13.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.1M | 2.6K |
| Earning Date | 01-06-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | 0.05 | ★ 0.36 |
| Revenue | ★ $114,319,869.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $15.56 | $38.33 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.59 | $6.55 |
| 52 Week High | $1.77 | $14.15 |
Technical Indicators
Market Signals| Indicator | ABLV | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 62.36 |
| Support Level | $0.74 | $12.00 |
| Resistance Level | $0.85 | $12.90 |
| Average True Range (ATR) | 0.09 | 0.38 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 11.41 | 97.95 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.